Martin Casapia
Overview
Explore the profile of Martin Casapia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
5574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rassi Jr A, Grimshaw A, Sarwal A, Sah R, Shah S, Higuita N, et al.
EClinicalMedicine
. 2025 Jan;
79():102972.
PMID: 39810938
Background: Endemic in more than 20 countries, Chagas disease affects 6.3 million people worldwide, leading to 28,000 new infections and 7700 deaths each year. Previous meta-analyses on antiparasitic treatment need...
2.
Reeves D, Mayer B, deCamp A, Huang Y, Zhang B, Carpp L, et al.
Nat Commun
. 2024 Mar;
15(1):2575.
PMID: 38519455
No abstract available.
3.
Magaret C, Li L, deCamp A, Rolland M, Juraska M, Williamson B, et al.
Nat Commun
. 2024 Mar;
15(1):2175.
PMID: 38467646
In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe-critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine...
4.
Reeves D, Mayer B, deCamp A, Huang Y, Zhang B, Carpp L, et al.
Nat Commun
. 2023 Dec;
14(1):8299.
PMID: 38097552
The Antibody Mediated Prevention (AMP) trials (NCT02716675 and NCT02568215) demonstrated that passive administration of the broadly neutralizing monoclonal antibody VRC01 could prevent some HIV-1 acquisition events. Here, we use mathematical...
5.
Rondon C, Garcia C, Krapp F, Machaca I, Olivera M, Fernandez V, et al.
J Infect Public Health
. 2023 Nov;
16 Suppl 1:52-60.
PMID: 37957105
Background: Peru reports higher levels than other countries in Latin America of resistance to antimicrobials among Gram-positive and Gram-negative bacteria, however data on antibiotic use in Peru are scarce. This...
6.
Magaret C, Li L, deCamp A, Rolland M, Juraska M, Williamson B, et al.
Res Sq
. 2023 Jul;
PMID: 37398105
It is of interest to pinpoint SARS-CoV-2 sequence features defining vaccine resistance. In the ENSEMBLE randomized, placebo-controlled phase 3 trial, estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate...
7.
Gyorkos T, Nicholls R, Montresor A, Lucianez A, Casapia M, St-Denis K, et al.
Rev Panam Salud Publica
. 2023 Mar;
47:e16.
PMID: 36909809
The objective of this manuscript is to provide selective examples of the work of the Pan American Health Organization/World Health Organization (PAHO/WHO) Collaborating Centre for Research and Training in Parasite...
8.
Krapp F, Rondon C, Amaro C, Barco-Yaipen E, Valera-Krumdieck M, Vasquez R, et al.
Am J Trop Med Hyg
. 2021 Dec;
106(2):432-440.
PMID: 34872054
Correct processing of blood cultures may impact individual patient management, antibiotic stewardship, and scaling up of antimicrobial resistance surveillance. To assess the quality of blood culture processing, we conducted four...
9.
Karuna S, Li S, Grant S, Walsh S, Frank I, Casapia M, et al.
PLoS Med
. 2021 Dec;
18(12):e1003868.
PMID: 34871308
Background: People infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) experience a wide range of clinical manifestations, from asymptomatic and mild illness to severe illness and death, influenced by...
10.
Huang Y, Seaton K, Casapia M, Polakowski L, De Rosa S, Cohen K, et al.
Vaccine
. 2021 Jul;
39(33):4641-4650.
PMID: 34229888
Background: Eliciting durable humoral immunity with sufficient breadth and magnitude is important for HIV-1 vaccine design. The HVTN 114 vaccine trial evaluated different boost regimens administered after a 7-year rest...